Ran Cheng, MD, FRCPC: Novo Nordisk: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
Learning Objectives / Objectifs d'apprentissage:
At the end of this session participants will be able to / Au terme de cette conférence, vous serez:
DEBATE THAT ANTI-OBESITY MEDICATION SHOULD BE THE FIRST LINE OF THERAPY FOR THOSE WITH CLASS III OBESITY;
DEBATE THAT BARIATRIC SURGERY SHOULD BE THE FIRST LINE OF THERAPY FOR THOSE WITH CLASS III OBESITY; and
DISCUSS THE PROS AND CONS OF EACH METHOD OF TREATMENT.
